135 related articles for article (PubMed ID: 32414570)
1. Simultaneous Stereotactic Radiofrequency Ablation of Multiple (≥ 4) Liver Tumors: Feasibility, Safety, and Efficacy.
Schullian P; Putzer D; Eberle G; Laimer G; Bale R
J Vasc Interv Radiol; 2020 Jun; 31(6):943-952. PubMed ID: 32414570
[TBL] [Abstract][Full Text] [Related]
2. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome.
Liu D; Liu M; Su L; Wang Y; Zhang X; Long H; Kuang M; Xie X; Lin M
J Vasc Interv Radiol; 2019 Dec; 30(12):1879-1886. PubMed ID: 31669087
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiofrequency ablation as first-line treatment of recurrent HCC following hepatic resection.
Schullian P; Laimer G; Putzer D; Levy E; Braunwarth E; Stättner S; Bale R
Eur J Surg Oncol; 2020 Aug; 46(8):1503-1509. PubMed ID: 32222261
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors.
Schullian P; Johnston EW; Putzer D; Eberle G; Laimer G; Bale R
Sci Rep; 2020 Jan; 10(1):1618. PubMed ID: 32005871
[TBL] [Abstract][Full Text] [Related]
5. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.
Wang F; Numata K; Takeda A; Ogushi K; Fukuda H; Nihonmatsu H; Hara K; Chuma M; Tsurugai Y; Maeda S
BMC Cancer; 2021 Oct; 21(1):1169. PubMed ID: 34717577
[TBL] [Abstract][Full Text] [Related]
6. Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis.
Chu HH; Kim JH; Yoon HK; Ko HK; Gwon DI; Kim PN; Sung KB; Ko GY; Kim SY; Park SH
J Vasc Interv Radiol; 2019 Oct; 30(10):1533-1543. PubMed ID: 31471190
[TBL] [Abstract][Full Text] [Related]
7. Feasibility, safety, and long-term efficacy of stereotactic radiofrequency ablation for tumors adjacent to the diaphragm in the hepatic dome: a case-control study.
Schullian P; Putzer D; Laimer G; Levy E; Bale R
Eur Radiol; 2020 Feb; 30(2):950-960. PubMed ID: 31489472
[TBL] [Abstract][Full Text] [Related]
8. Conventional Chemoembolization Plus Radiofrequency Ablation versus Surgical Resection for Single, Medium-Sized Hepatocellular Carcinoma: Propensity-Score Matching Analysis.
Lee HJ; Kim JW; Hur YH; Cho SB; Lee BC; Lee BK; Hwang EC; Cho YS; Seon HJ
J Vasc Interv Radiol; 2019 Mar; 30(3):284-292.e1. PubMed ID: 30819467
[TBL] [Abstract][Full Text] [Related]
9. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort.
Yoon HM; Kim JH; Kim EJ; Gwon DI; Ko GY; Ko HK
J Vasc Interv Radiol; 2013 Nov; 24(11):1639-46. PubMed ID: 23962438
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Radiofrequency Ablation for Breast Cancer Liver Metastases.
Bale R; Richter M; Dünser M; Levy E; Buchberger W; Schullian P
J Vasc Interv Radiol; 2018 Feb; 29(2):262-267. PubMed ID: 29273283
[TBL] [Abstract][Full Text] [Related]
11. Radiofrequency ablation for liver metastasis from gastrointestinal stromal tumor.
Yamanaka T; Takaki H; Nakatsuka A; Uraki J; Fujimori M; Hasegawa T; Sakuma H; Yamakado K
J Vasc Interv Radiol; 2013 Mar; 24(3):341-6. PubMed ID: 23352855
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence.
Schullian P; Johnston E; Laimer G; Scharll Y; Putzer D; Eberle G; Kolbitsch C; Amann A; Stättner S; Bale R
HPB (Oxford); 2022 Jul; 24(7):1044-1054. PubMed ID: 34887174
[TBL] [Abstract][Full Text] [Related]
13. A comparison of US-guided percutaneous radiofrequency ablation of medium-sized hepatocellular carcinoma with a cluster electrode or a single electrode with a multiple overlapping ablation technique.
Park MJ; Kim YS; Rhim H; Lim HK; Lee MW; Choi D
J Vasc Interv Radiol; 2011 Jun; 22(6):771-9. PubMed ID: 21616430
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiofrequency ablation (SRFA) for recurrent colorectal liver metastases after hepatic resection.
Schullian P; Johnston EW; Putzer D; Laimer G; Waroschitz G; Braunwarth E; Amann A; Maglione M; Bale R
Eur J Surg Oncol; 2021 Apr; 47(4):866-873. PubMed ID: 33032865
[TBL] [Abstract][Full Text] [Related]
15. Small- and medium-sized hepatocellular carcinomas: monopolar radiofrequency ablation with a multiple-electrode switching system-mid-term results.
Woo S; Lee JM; Yoon JH; Joo I; Kim SH; Lee JY; Yoon JH; Kim YJ; Han JK; Choi BI
Radiology; 2013 Aug; 268(2):589-600. PubMed ID: 23513241
[TBL] [Abstract][Full Text] [Related]
16. Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin.
Celik H; Wakim P; Pritchard WF; Castro M; Leonard S; Karanian JW; Dewhirst MW; Lencioni R; Wood BJ
J Vasc Interv Radiol; 2019 Dec; 30(12):1908-1914. PubMed ID: 31409568
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic radiofrequency ablation of subcardiac hepatocellular carcinoma: a case-control study.
Schullian P; Johnston EW; Putzer D; Eberle G; Laimer G; Bale R
Int J Hyperthermia; 2019; 36(1):876-885. PubMed ID: 31462110
[No Abstract] [Full Text] [Related]
18. Stereotactic Radiofrequency Ablation of Breast Cancer Liver Metastases: Short- and Long-Term Results with Predicting Factors for Survival.
Schullian P; Johnston E; Laimer G; Putzer D; Eberle G; Scharll Y; Ianetti-Hackl C; Bale R
Cardiovasc Intervent Radiol; 2021 Aug; 44(8):1184-1193. PubMed ID: 33825059
[TBL] [Abstract][Full Text] [Related]
19. Microwave versus Radiofrequency Ablation Treatment for Hepatocellular Carcinoma: A Comparison of Efficacy at a Single Center.
Potretzke TA; Ziemlewicz TJ; Hinshaw JL; Lubner MG; Wells SA; Brace CL; Agarwal P; Lee FT
J Vasc Interv Radiol; 2016 May; 27(5):631-8. PubMed ID: 27017124
[TBL] [Abstract][Full Text] [Related]
20. Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.
Huang YH; Park BV; Chen YF; Gaba RC; Guzman G; Lokken RP
J Vasc Interv Radiol; 2019 Sep; 30(9):1317-1324. PubMed ID: 31375450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
